BioTuesdays

Category - Markets

NRx-Pharma-Logo
Markets

Dawson James ups NRx Pharma PT to $9 from $3

Dawson James Securities raised its price target for NRx Pharmaceuticals (NASDAQ:NRXP) to $9 from $3, saying the company’s NRX-101 drug candidate could change the treatment paradigm for depression, PTSD, and related...

April 3, 2023
MDXHealth-logo
Markets

WB starts MDxHealth at outperform

William Blair launched coverage of MDxHealth S.A. (NASDAQ:MDXH) with an “outperform” rating. The stock closed at $2.86 on March 23. Analyst Andrew Brackmann writes that the rating is based on his belief that the company...

March 24, 2023
NRx-Pharma-Logo
Markets

Dawson James starts NRx Pharma at buy; PT $3.00

Dawson James Securities initiated coverage of NRx Pharmaceuticals (NASDAQ:NRXP) with a “buy” rating and $3.00 price target. The stock closed at 68 cents on March 16. NRx Pharmaceuticals is a clinical-stage...

March 17, 2023
Theseus-Logo
Markets

Stifel starts Theseus Pharma at buy; PT $24

Stifel initiated coverage of Theseus Pharmaceuticals (NASDAQ:THRX) with a “buy” rating and $24 price target. The stock closed at $7.35 on March 15. Theseus is a clinical-stage, small molecule oncology company that...

March 16, 2023
CymaBay-Logo
Markets

BTIG starts CymaBay at buy; PT $15

BTIG launched coverage of CymaBay Therapeutics (NASDAQ:CBAY) with a “buy” rating and $15 price target. The stock closed at $9.11 on March 8. Analyst Julian Harrison writes that the company’s seladelpar is well...

March 9, 2023
Mesoblast-Logo
Markets

WB starts Mesoblast at OP; fair value estimate $8

William Blair initiated coverage of Mesoblast (NASDAQ:MESO) with an “outperform” rating and fair value estimate of $8. The stock closed at $3.03 on March 8. Mesoblast is developing mesenchymal lineage cell-derived...

March 9, 2023
MoonLake Logo
Markets

BTIG starts Moonlake at buy; PT $36

BTIG initiated coverage of Moonlake Immunotherapeutics (NASDAQ:MLTX) with a “buy” rating and $36 price target. The stock closed at $23.70 on March 8. “We see Moonlake’s sonelokimab (SLK) well-positioned to emerge as the...

March 9, 2023